



9th July, 2016

To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DISHMAN (ii) Series – EQ	To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref. : Scrip Code No. : 532526
---	---

Sub. Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015

Dear Sir,

With reference to the captioned subject, we would like to inform that renewal of US FDA inspection of Company's Bavla facility has been successfully completed on 8th July, 2016.

Kindly take this on your record.

Thanking you.

Yours faithfully,
For Dishman Pharmaceuticals and Chemicals Limited

S.G. Dave
Shrima Dave
Compliance Officer



Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329